Status:
TERMINATED
Effect of PARP Inhibitors on Glomerular Filtration Rate
Lead Sponsor:
University of Pennsylvania
Conditions:
Solid Tumor
Ovarian Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function...
Detailed Description
PARPi medications interact with transporters along the renal tubules involved in the secretion of creatinine and an increase in serum creatinine is often observed in patients treated with these agents...
Eligibility Criteria
Inclusion
- Adult patients age 18 years or older
- Diagnosed with any solid organ cancer
- Planned to receive a PARP inhibitor (olaparib, niraparib, rucaparib, veliparib, or talazoparib)
- Able to consent to study related procedures
- If unable to give informed consent, must have healthcare proxy or legally authorized representative
- Fluent in conversational English (Informed Consent form currently in English language)
Exclusion
- Patients who will not receive ongoing cancer care at Penn Medicine
- Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation
- Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff
- Patients on dialysis
Key Trial Info
Start Date :
February 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04367467
Start Date
February 3 2020
End Date
July 1 2021
Last Update
January 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104